BGM
DYN icon

Burkehill Global Management’s Dyne Therapeutics DYN Stock Holding History

Burkehill Global Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.81M Hold
155,000
– – 0.14% 109
2025
Q4 		$3.03M Buy
155,000
+35,000
+29% +$663K 0.2% 99
2025
Q3 		$1.52M Buy
+120,000
New +$1.37M 0.09% 127

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Burkehill Global Management's DYN Position: Q1 2026 in Review

Burkehill Global Management held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 155,000 shares worth $2.81M. The position accounts for 0.14% of the portfolio, ranked #109.

Burkehill Global Management first reported a position in DYN in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.03M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Burkehill Global Management held 155,000 shares of Dyne Therapeutics worth $2.81M as of Q1 2026.
  • Burkehill Global Management left its Dyne Therapeutics share count unchanged in Q1 2026.
  • Dyne Therapeutics made up 0.14% of Burkehill Global Management's portfolio in Q1 2026, its #109 holding.
  • Burkehill Global Management first reported a position in Dyne Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Burkehill Global Management's Dyne Therapeutics position peaked at $3.03M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.